Denton, TX (PRWEB) March 28, 2013
US Radiopharmaceuticals (USR) announced today that it has awarded Von Gahlen International the contract to design, develop, and install the hot cells and ancillary equipment to be utilized in its USR Denton Tc-99m generator facility scheduled for opening in early 2014. Located in Chatsworth, GA, Von Gahlen is recognized as the industry leader in lead shielded products for the nuclear medicine industry that meets or exceeds industry standards and federal and state safety requirements.
In 2012, USR and the Australian Nuclear Science and Technology Organisation (ANSTO) entered into an exclusive license agreement to enable USR to manufacture the Australian designed Tc-99m generators, which utilize molybdenum-99 (Mo-99). The 20-year agreement represents the start of a long-term strategic partnership, between ANSTO and US Radiopharmaceuticals that will lead to the establishment of a high capacity production facility at the existing USR manufacturing site in Denton, Texas. The agreement allows for the exclusive distribution of the ANSTO generator in the Americas. The new line will be capable of producing up to 90% of the demand for Tc-99m throughout North and South America.
Under the terms of the agreement, USR will become the only U.S. generator manufacturer to exclusively use Mo-99 produced from Low Enriched Uranium (LEU) in all of their generators. In addition, USR has signed an agreement for the supply of Mo-99 to load these generators. ANSTO and its’ partner NTP of South Africa, are committed to meet the supply requirements of USR for Mo-99 once their facility is operational. This Mo-99 sourced from the ANSTO Open Pool Australian Lightwater (OPAL) reactor in Australia and the NTP Radioisotopes SAFARI-1 reactor in South Africa will be produced solely using LEU.
The ANSTO generators, having been used routinely in Australia and other countries for over 30 years, are fully compa
Copyright©2012 Vocus, Inc.
All rights reserved